Comments from the Editor of the Special Issue “Type 2 Diabetes: Update on Pathophysiology and Treatment”

Comments from the Editor of the Special Issue “Type 2 Diabetes: Update on Pathophysiology and Treatment”

The editor would like to offer the Special Issue “Type 2 Diabetes: Update on Pathophysiology and Treatment” to the community of diabetes clinicians and researchers. This Special Issue aims to update our understanding of the pathophysiology and treatment of type 2 diabetes and its...

Full description

Bibliographic Details
Main Author:	Tomoaki Morioka
Format:	Article
Language:	English
Published:	MDPI AG 2019-11-01
Series:	Journal of Clinical Medicine
Subjects:	type 2 diabetes obesity kidney disease cancer elderly microbiota microrna deep neural network glucagon-like peptide-1 dementia bariatric surgery
Online Access:	https://www.mdpi.com/2077-0383/8/11/1939

Similar Items

Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus
by: I I Larina, et al.
Published: (2018-10-01)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01)

A Glucagon-Like Peptide-1 Receptor Agonist Lowers Weight by Modulating the Structure of Gut Microbiota
by: Li Zhao, et al.
Published: (2018-05-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
by: Mahmoud M Mosli, et al.
Published: (2017-01-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-04-01)

Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
by: Riying Liang, et al.
Published: (2020-10-01)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
by: L. Kořínková, et al.
Published: (2020-11-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2019-03-01)

Effect of Pro-Kinetic Drugs on Post –Prandial Glycaemic Surge in Type 2 Diabetic Patients
by: Asim Zulfiqar
Published: (2012-12-01)

GLP-1 effects on pancreatic b-cell lines
by: Sinclair, Elaine M.
Published: (2002)

Effects of Fasting on Glucagon-like peptide-1 hormone (GLP-1), and Lipid Profile Indices in Obese and Thin Women
by: Shahrbanoo Haghighi, et al.
Published: (2019-03-01)

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
by: Inoue Kana, et al.
Published: (2011-12-01)

Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

Preliminary results from digestive adaptation: a new surgical proposal for treating obesity, based on physiology and evolution
by: Sérgio Santoro, et al.

Pleiotropic effects of incretins
by: Vishal Gupta
Published: (2012-01-01)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013-06-01)

Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial
by: Aditi R. Saxena, et al.
Published: (2021-06-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-10-01)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019-08-01)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
by: Yun Kyung Jeon, et al.
Published: (2014-12-01)

In vitro and in vivo effects of exendin-4 on human islet amyloid polypeptide induced beta-cell dysfunction.
Published: (2013)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Treatment with Glucagon-Like Peptide-1 Analogues — a Breakthrough in Diabetes Mellitus Type 2 Therapy
by: V.L. Orlenko, et al.
Published: (2014-05-01)

New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
by: Won-Young Lee
Published: (2017-02-01)

Inquiry into the short- and long-term effects of Roux-en-Y gastric bypass on the glomerular filtration rate
by: Allon N. Friedman, et al.
Published: (2020-01-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
by: Shinje Moon, et al.
Published: (2021-06-01)

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

South American herbal extracts reduce food intake through modulation of gastrointestinal hormones in overweight and obese women
by: Marina Monteiro Celestino, et al.
Published: (2017-08-01)

Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
by: Fang Han, et al.
Published: (2019-12-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity
by: Yuko Maejima, et al.
Published: (2021-06-01)

The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
by: Baocheng Xie, et al.
Published: (2021-06-01)

Diet, Bariatric Surgery and Gut Microbiota
by: Aslıhan Özdemir, et al.
Published: (2018-09-01)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
by: Yu Mi Kang, et al.
Published: (2016-06-01)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
by: Ali Asmar, et al.
Published: (2020-08-01)